Recent Company News

• 09:03 AM ET Jul 22, 2025
  

  Roche Canada announces Polivy for First-Line Treatment of Adults With Large B-Cell Lymphoma is now Publicly Reimbursed in Québec (CHF 253.40, -2.20)

• 08:17 PM ET Jul 21, 2025
  

  Sarepta Therapeutics to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the U.S., effective 22-Jul ($13.32, 0.00)

• 11:00 PM ET Jun 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 03:05 AM ET Jul 07, 2025
  

  Chugai Pharmaceutical, Singapore Gero PTE enter joint research and license agreement to develop novel therapies for age-related diseases (¥7140.0000, 0)

• 08:21 PM ET Jul 01, 2025
  

  NICE recommends Chugai Pharmaceutical's Nemluvio to treat moderate to severe atopic dermatitis in people 12 years and over (¥7064.0000, -173)

• 02:46 AM ET Jun 26, 2025
  

  Chugai Pharmaceutical applies for additional tumor-agnostic indication of Alecensa with MHLW (¥7583.0000, 0)

• 01:08 AM ET Jun 25, 2025
  

  Galderma Group initiates two new clinical trials investigating nemolizumab in patients with systemic sclerosis and chronic pruritus of unknown origin (CHF 111.30, 0.00)

• 04:22 PM ET Jun 24, 2025
  

  FDA investigating deaths due to acute liver failure in non-ambulatory Duchenne Muscular Dystrophy patients following treatment with Sarepta Therapeutics' ELEVIDYS ($18.98, 0.00)

• 12:16 AM ET Jun 23, 2025
  

  Chugai Pharmaceutical presents first clinical data in people with hemophilia A from phase I/II study of NXT007 (11:34 JT) (¥7501.0000, +312)